{"ticker": {"uuid": "4e57039b-4e7e-450f-85f7-d0d4483c41ad", "symbol": "PALI", "name": "Palisade Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased $88,698 worth of the company's common stock through multiple transactions on July 8 and 9, 2026, increasing his direct ownership to 461,904 shares. These insider purchases follow the company's stock delivering a 151% ret", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-purchases-88698-in-stock-93CH-4787095", "source_name": "Investing.com", "published_at": "2026-07-11T20:11:13", "published_display": "11 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Palisade Bio, Inc. \u2013 LS:A4098S", "summary": "The article provides financial information for Palisade Bio, Inc. (A4098S) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from the platform, indicating the market status, and offering various financial tool", "url": "https://www.tradingview.com/symbols/LS-A4098S/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T15:09:25", "published_display": "11 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Participate in the Leerink Partners Therapeutics Forum", "summary": "Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will attend the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to meet with institutional investo", "url": "https://www.globenewswire.com/fr/news-release/2026/07/10/3325498/0/en/palisade-bio-to-participate-in-the-leerink-partners-therapeutics-forum.html", "source_name": "GlobeNewswire", "published_at": "2026-07-11T09:42:52", "published_display": "11 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc (PALI) dated July 10. The filing indicates some sort of insider transaction or change in ownership, though specific details are not provided beyond the date and the company name. The article also incl", "url": "https://ng.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-10-july-93CH-2595704", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T08:10:50", "published_display": "11 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) director adds 45,000 shares through July open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. made two open-market purchases of common stock in July 2026, acquiring a total of 45,000 shares. These transactions increased his direct holdings to 461,904 shares, signaling positive sentiment towards the company. The purchases were execu", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-ffa589425a04.html", "source_name": "Stock Titan", "published_at": "2026-07-11T07:40:49", "published_display": "11 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PALISADE BIO, INC. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by PALISADE BIO, INC. (PALI) on July 7, 2026. The filing indicates a proposed sale of 53,000 shares of common stock with an aggregate market value of $108,120.00, acquired via RSU from the issuer on the same date. The filing also incl", "url": "https://www.stocktitan.net/sec-filings/PALI/144-palisade-bio-inc-sec-filing-fbb2523d202e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:09:38", "published_display": "10 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to present clinical updates at Leerink Partners Therapeutics Forum in July 2026", "summary": "Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO and President will attend the Leerink Partners Therapeutics Forum in July 2026. They will engage in one-on-one meetings with investors to discuss the company's clinical development strategy and the p", "url": "https://pluang.com/en/news-feed/palisade-bio-ikut-forum-terapeutik-leerink-partners", "source_name": "Pluang", "published_at": "2026-07-10T13:40:39", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio leaders set to outline IBD drug plans at Boston forum", "summary": "Palisade Bio (Nasdaq: PALI) announced that its CEO and President & CMO will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to hold one-on-one meetings with institutional investors to discuss the company's clinical development stra", "url": "https://www.stocktitan.net/news/PALI/palisade-bio-to-participate-in-the-leerink-partners-therapeutics-aei7u880ni8f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:40:39", "published_display": "10 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOc1loOUJiamtlUV83NU9tc3hYUDhxelBpd3Ytdk1jVmsxMWtZMWZYQU8yNWtKTFJBSkJJTkJpWXRKeFVFVWt1bTB5QkE4dEJHMnNiUFNHb2h5a3RzcTRSMTVReW4tN2hYNnNTR014TmliZE1xNGxjVmJrS1YxWFg4R0QzcUJEd1Nkc0hiZzlJSDNPV2gzRkswUl8wclRzT2tZem93TlhCUms4dW5uNkhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:06:41+00:00", "published_display": "10 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn\u2019s Disease Markets (PALI)", "summary": "Palisade Bio (PALI) presents a speculative, early-stage investment opportunity with PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn\u2019s disease, having shown promising Phase 1 results. The company's $132.6 million cash runway provides funding through key Phase 2 readout", "url": "https://seekingalpha.com/article/4921082-palisade-bio-a-unique-moa-targeting-the-uc-and-crohns-disease-markets", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:06:38", "published_display": "10 Jul 2026 07:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com", "summary": "Palisade Bio's CEO and CFO, John David Finley, sold 146,798 shares totaling $303,343 to cover tax obligations from vested restricted stock units, despite the stock's 184% return over the past year. Earlier, Finley acquired 335,167 shares from RSU settlements and 133 shares from w", "url": "https://ng.investing.com/news/stock-market-news/palisade-bio-ceo-cfo-finley-sells-303k-in-stock-93CH-2592032", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T23:45:53", "published_display": "09 Jul 2026 23:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio chief medical officer Jones sells $106,535 in stock", "summary": "Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, sold 51,880 shares of company stock for $106,535 to cover tax obligations from vested Restricted Stock Units (RSUs). Prior to this sale, he acquired 131,167 shares through RSU settlements, and he now holds 94,009 shar", "url": "https://ng.investing.com/news/stock-market-news/palisade-bio-chief-medical-officer-jones-sells-106535-in-stock-93CH-2592042", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T07:11:38", "published_display": "09 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio CEO, CFO Finley sells $303k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWFB4bzZxMTc4Y0hTY09taWV0ZUhheXdFVzZsM1piZmlJYmNyY3pJTVR1RlJZNmVoNVNjUUFqYWVfbk5saHJncFdLamhSZ2ExdkhVX2RITXdxeGY5SmlSLXNFQVZRSFJxSEZHTzk1dGxBdmpYaVJtV05MTmg2YWxDMnBOWjlqekJ6dlh2cmM5QnhENWw4bFg0ZTk3Rlc5ZjNSY2RkM1NQamlrb1pUS0oxZS1n?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T22:58:07+00:00", "published_display": "08 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc, dated July 8th. Form 4s disclose transactions made by company insiders. The article indicates that Palisade Bio Inc (PALI) experienced a -4.15% change in its stock.", "url": "https://ng.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-8-july-93CH-2592038", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:45:53", "published_display": "08 Jul 2026 23:45", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com", "summary": "Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, sold 51,880 shares of the company's common stock for $106,535 to cover tax withholding obligations. This sale followed his acquisition of 131,167 shares through vested Restricted Stock Units. The company recently rec", "url": "https://m.za.investing.com/news/stock-market-news/palisade-bio-chief-medical-officer-jones-sells-106535-in-stock-93CH-4361495?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T23:40:50", "published_display": "08 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio director Robert Baltera Jr. buys $102,084 in stock", "summary": "Palisade Bio director Robert Baltera Jr. purchased $102,084 worth of company stock across two days, acquiring 50,000 shares in total, bringing his direct holdings to 416,904 shares. This insider buying occurs as PALI shares have seen a significant annual surge but are down year-t", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-buys-102084-in-stock-93CH-4782793", "source_name": "Investing.com", "published_at": "2026-07-08T23:40:49", "published_display": "08 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax", "summary": "Palisade Bio (PALI) CEO and CFO John David Finley reported a routine equity compensation activity, including the vesting of Restricted Stock Units (RSUs) and a small warrant exercise. Finley acquired 335,167 common", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-b36143e25a15.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:50", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased 50,000 shares of common stock in open-market transactions over two days. These purchases, totaling over $102,000, increased his direct ownership to 416,904 shares. The transactions underscore a positive sentiment from an", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-d69acd08e07b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:49", "published_display": "08 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PALISADE BIO, INC. Insider Trading Activity", "summary": "This article details the insider trading activity of Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, Inc. (PALI), as reported in a Form 4 SEC filing. The activity primarily involves the exercise of restricted stock units (RSUs) and a subsequent sale of shares to c", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-216c0e2b577f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:49", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$59k Buying More Shares In Palisade Bio", "summary": "Palisade Bio's Independent Director, Robert Baltera, recently purchased US$59k worth of company stock, increasing his shareholding by 8.9%. This insider buying activity, the largest in the past year, suggests optimism about the company despite its current losses and low overall i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pali/palisade-bio/news/insider-spends-us59k-buying-more-shares-in-palisade-bio", "source_name": "Simply Wall Street", "published_at": "2026-07-08T10:39:22", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 PALISADE BIO For: 7 July By Investing.com", "summary": "Investing.com reported on Form 144 for PALISADE BIO on July 7th. The article is a brief financial update indicating the filing of a Form 144, which relates to the proposed sale of restricted securities. It also includes general market data and other news.", "url": "https://ng.investing.com/news/stock-market-news/form-144-palisade-bio-for-7-july-93CH-2589899", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:04:00", "published_display": "07 Jul 2026 22:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio director Robert Baltera Jr. buys $59,400 in stock", "summary": "Robert Baltera Jr., a director at Palisade Bio (NASDAQ:PALI), recently purchased 30,000 shares of company stock for $59,400, bringing his total direct holdings to 366,904 shares. This insider buying follows the FDA's clearance for Palisade Bio's Phase 2 clinical trial of PALI-210", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-buys-59400-in-stock-93CH-4778059", "source_name": "Investing.com", "published_at": "2026-07-07T00:41:25", "published_display": "07 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) director adds 30,000 shares in open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased 30,000 shares of the company's common stock through open-market transactions at a weighted average price of $1.98 per share. These purchases, totaling $59,400, have increased his direct holdings to 366,904 shares, signal", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-b7f6efe6f6ef.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:41:25", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 6 July By Investing.com", "summary": "The article reports that Palisade Bio Inc. filed a Form 4 for July 6th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. The article provides minimal details b", "url": "https://ca.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-6-july-93CH-4722017", "source_name": "Investing.com Canada", "published_at": "2026-07-06T23:41:25", "published_display": "06 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palisade Bio, Inc. \u2013 NASDAQ:PALI", "summary": "This article focuses on the \"Price to book forward\" financial metric for Palisade Bio, Inc. (NASDAQ: PALI). It appears to be a financial data point provided by TradingView, without additional analysis or details. The content is primarily a data placeholder within a financial plat", "url": "https://www.tradingview.com/symbols/NASDAQ-PALI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:31", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palisade Bio, Inc. \u2013 NASDAQ:PALI", "summary": "This article provides a brief snapshot of Palisade Bio, Inc. (NASDAQ: PALI) on TradingView, focusing on its financial overview. It mentions the company's stock information, market status, and available financial data. The content is primarily a data placeholder, indicating a lack", "url": "https://www.tradingview.com/symbols/NASDAQ-PALI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:10:24", "published_display": "04 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palisade-bio-gets-fda-ind-130329630.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:03:29+00:00", "published_display": "29 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palisade-bio-receives-fda-clearance-123000813.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:30:00+00:00", "published_display": "29 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-welcomes-biopharmaceutical-industry-124500803.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:45:00+00:00", "published_display": "11 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn\u2019s Disease at New York Academy of Sciences Symposium", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-present-potential-pali-124500883.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:45:00+00:00", "published_display": "09 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-participate-jefferies-global-130000252.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T13:00:00+00:00", "published_display": "27 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQaHVrRV96dmxzcHNMZDQ2c2JVNThnTHZnNGFzX1UyU1U4NWtWcG0yeVh4UFJXN01oQ0h5dHN1YXJBUVVsR3c2YklWTHh5VUR6S2FUNy13QjhiVFk2ZlJtWDU1VTE0clZCMXBfdGdhRU5QSk5EektPdG1MQnctX0dqN2VEOWtfX3Ribnd2Q2pMbkNuRzhpeFIzTlRRbnU5Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palisade Bio Announces 1-for-15 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQQ0FIRDNzVHkyeW85dTRSbmw5bFYzWER4UjlDZUdaYnFON1diV1A0RE1Zd01JdW5uNHMtRE1kVElLbnFtZTZ4cFFjOTF6MGo3aGdyZVFyQ1BJVDNMY1p6VWk3aS0xdFVYYk42VXZDSEV1bHJqdzhBd1NnQXd3cGxsWmxHMXpjRUZ1N2tXTWJyZ0JxdDE5enMteEc0SHAtaEFqRFZsR3pBeEx4b3M3emlFVF9ILTZqV3U3OUJ3NlptQV82Ukdm?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-04-03T07:00:00+00:00", "published_display": "03 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased $88,698 worth of the company's common stock through multiple transactions on July 8 and 9, 2026, increasing his direct ownership to 461,904 shares. These insider purchases follow the company's stock delivering a 151% ret", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-purchases-88698-in-stock-93CH-4787095", "source_name": "Investing.com", "published_at": "2026-07-11T20:11:13", "published_display": "11 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Palisade Bio, Inc. \u2013 LS:A4098S", "summary": "The article provides financial information for Palisade Bio, Inc. (A4098S) on TradingView, specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from the platform, indicating the market status, and offering various financial tool", "url": "https://www.tradingview.com/symbols/LS-A4098S/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T15:09:25", "published_display": "11 Jul 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Participate in the Leerink Partners Therapeutics Forum", "summary": "Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will attend the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to meet with institutional investo", "url": "https://www.globenewswire.com/fr/news-release/2026/07/10/3325498/0/en/palisade-bio-to-participate-in-the-leerink-partners-therapeutics-forum.html", "source_name": "GlobeNewswire", "published_at": "2026-07-11T09:42:52", "published_display": "11 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 10 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc (PALI) dated July 10. The filing indicates some sort of insider transaction or change in ownership, though specific details are not provided beyond the date and the company name. The article also incl", "url": "https://ng.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-10-july-93CH-2595704", "source_name": "Investing.com Nigeria", "published_at": "2026-07-11T08:10:50", "published_display": "11 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) director adds 45,000 shares through July open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. made two open-market purchases of common stock in July 2026, acquiring a total of 45,000 shares. These transactions increased his direct holdings to 461,904 shares, signaling positive sentiment towards the company. The purchases were execu", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-ffa589425a04.html", "source_name": "Stock Titan", "published_at": "2026-07-11T07:40:49", "published_display": "11 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] PALISADE BIO, INC. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by PALISADE BIO, INC. (PALI) on July 7, 2026. The filing indicates a proposed sale of 53,000 shares of common stock with an aggregate market value of $108,120.00, acquired via RSU from the issuer on the same date. The filing also incl", "url": "https://www.stocktitan.net/sec-filings/PALI/144-palisade-bio-inc-sec-filing-fbb2523d202e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T22:09:38", "published_display": "10 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to present clinical updates at Leerink Partners Therapeutics Forum in July 2026", "summary": "Palisade Bio, a clinical-stage biopharmaceutical company, announced that its CEO and President will attend the Leerink Partners Therapeutics Forum in July 2026. They will engage in one-on-one meetings with investors to discuss the company's clinical development strategy and the p", "url": "https://pluang.com/en/news-feed/palisade-bio-ikut-forum-terapeutik-leerink-partners", "source_name": "Pluang", "published_at": "2026-07-10T13:40:39", "published_display": "10 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio leaders set to outline IBD drug plans at Boston forum", "summary": "Palisade Bio (Nasdaq: PALI) announced that its CEO and President & CMO will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. They plan to hold one-on-one meetings with institutional investors to discuss the company's clinical development stra", "url": "https://www.stocktitan.net/news/PALI/palisade-bio-to-participate-in-the-leerink-partners-therapeutics-aei7u880ni8f.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:40:39", "published_display": "10 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOc1loOUJiamtlUV83NU9tc3hYUDhxelBpd3Ytdk1jVmsxMWtZMWZYQU8yNWtKTFJBSkJJTkJpWXRKeFVFVWt1bTB5QkE4dEJHMnNiUFNHb2h5a3RzcTRSMTVReW4tN2hYNnNTR014TmliZE1xNGxjVmJrS1YxWFg4R0QzcUJEd1Nkc0hiZzlJSDNPV2gzRkswUl8wclRzT2tZem93TlhCUms4dW5uNkhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:06:41+00:00", "published_display": "10 Jul 2026 07:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Stock: A Unique MoA Targeting The UC And Crohn\u2019s Disease Markets (PALI)", "summary": "Palisade Bio (PALI) presents a speculative, early-stage investment opportunity with PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn\u2019s disease, having shown promising Phase 1 results. The company's $132.6 million cash runway provides funding through key Phase 2 readout", "url": "https://seekingalpha.com/article/4921082-palisade-bio-a-unique-moa-targeting-the-uc-and-crohns-disease-markets", "source_name": "Seeking Alpha", "published_at": "2026-07-10T07:06:38", "published_display": "10 Jul 2026 07:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio CEO, CFO Finley sells $303k in stock By Investing.com", "summary": "Palisade Bio's CEO and CFO, John David Finley, sold 146,798 shares totaling $303,343 to cover tax obligations from vested restricted stock units, despite the stock's 184% return over the past year. Earlier, Finley acquired 335,167 shares from RSU settlements and 133 shares from w", "url": "https://ng.investing.com/news/stock-market-news/palisade-bio-ceo-cfo-finley-sells-303k-in-stock-93CH-2592032", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T23:45:53", "published_display": "09 Jul 2026 23:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio chief medical officer Jones sells $106,535 in stock", "summary": "Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, sold 51,880 shares of company stock for $106,535 to cover tax obligations from vested Restricted Stock Units (RSUs). Prior to this sale, he acquired 131,167 shares through RSU settlements, and he now holds 94,009 shar", "url": "https://ng.investing.com/news/stock-market-news/palisade-bio-chief-medical-officer-jones-sells-106535-in-stock-93CH-2592042", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T07:11:38", "published_display": "09 Jul 2026 07:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio CEO, CFO Finley sells $303k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQWFB4bzZxMTc4Y0hTY09taWV0ZUhheXdFVzZsM1piZmlJYmNyY3pJTVR1RlJZNmVoNVNjUUFqYWVfbk5saHJncFdLamhSZ2ExdkhVX2RITXdxeGY5SmlSLXNFQVZRSFJxSEZHTzk1dGxBdmpYaVJtV05MTmg2YWxDMnBOWjlqekJ6dlh2cmM5QnhENWw4bFg0ZTk3Rlc5ZjNSY2RkM1NQamlrb1pUS0oxZS1n?oc=5", "source_name": "Investing.com", "published_at": "2026-07-08T22:58:07+00:00", "published_display": "08 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 8 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Palisade Bio Inc, dated July 8th. Form 4s disclose transactions made by company insiders. The article indicates that Palisade Bio Inc (PALI) experienced a -4.15% change in its stock.", "url": "https://ng.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-8-july-93CH-2592038", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T23:45:53", "published_display": "08 Jul 2026 23:45", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio chief medical officer Jones sells $106,535 in stock By Investing.com", "summary": "Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, sold 51,880 shares of the company's common stock for $106,535 to cover tax withholding obligations. This sale followed his acquisition of 131,167 shares through vested Restricted Stock Units. The company recently rec", "url": "https://m.za.investing.com/news/stock-market-news/palisade-bio-chief-medical-officer-jones-sells-106535-in-stock-93CH-4361495?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-07-08T23:40:50", "published_display": "08 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio director Robert Baltera Jr. buys $102,084 in stock", "summary": "Palisade Bio director Robert Baltera Jr. purchased $102,084 worth of company stock across two days, acquiring 50,000 shares in total, bringing his direct holdings to 416,904 shares. This insider buying occurs as PALI shares have seen a significant annual surge but are down year-t", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-buys-102084-in-stock-93CH-4782793", "source_name": "Investing.com", "published_at": "2026-07-08T23:40:49", "published_display": "08 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) CEO Finley sells shares to cover RSU tax", "summary": "Palisade Bio (PALI) CEO and CFO John David Finley reported a routine equity compensation activity, including the vesting of Restricted Stock Units (RSUs) and a small warrant exercise. Finley acquired 335,167 common", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-b36143e25a15.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:50", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Palisade Bio (PALI) adds 50,000 shares in open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased 50,000 shares of common stock in open-market transactions over two days. These purchases, totaling over $102,000, increased his direct ownership to 416,904 shares. The transactions underscore a positive sentiment from an", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-d69acd08e07b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:49", "published_display": "08 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PALISADE BIO, INC. Insider Trading Activity", "summary": "This article details the insider trading activity of Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, Inc. (PALI), as reported in a Form 4 SEC filing. The activity primarily involves the exercise of restricted stock units (RSUs) and a subsequent sale of shares to c", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-216c0e2b577f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:49", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Spends US$59k Buying More Shares In Palisade Bio", "summary": "Palisade Bio's Independent Director, Robert Baltera, recently purchased US$59k worth of company stock, increasing his shareholding by 8.9%. This insider buying activity, the largest in the past year, suggests optimism about the company despite its current losses and low overall i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pali/palisade-bio/news/insider-spends-us59k-buying-more-shares-in-palisade-bio", "source_name": "Simply Wall Street", "published_at": "2026-07-08T10:39:22", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 PALISADE BIO For: 7 July By Investing.com", "summary": "Investing.com reported on Form 144 for PALISADE BIO on July 7th. The article is a brief financial update indicating the filing of a Form 144, which relates to the proposed sale of restricted securities. It also includes general market data and other news.", "url": "https://ng.investing.com/news/stock-market-news/form-144-palisade-bio-for-7-july-93CH-2589899", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:04:00", "published_display": "07 Jul 2026 22:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio director Robert Baltera Jr. buys $59,400 in stock", "summary": "Robert Baltera Jr., a director at Palisade Bio (NASDAQ:PALI), recently purchased 30,000 shares of company stock for $59,400, bringing his total direct holdings to 366,904 shares. This insider buying follows the FDA's clearance for Palisade Bio's Phase 2 clinical trial of PALI-210", "url": "https://www.investing.com/news/insider-trading-news/palisade-bio-director-robert-baltera-jr-buys-59400-in-stock-93CH-4778059", "source_name": "Investing.com", "published_at": "2026-07-07T00:41:25", "published_display": "07 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) director adds 30,000 shares in open-market buys", "summary": "Palisade Bio director Robert Baltera Jr. recently purchased 30,000 shares of the company's common stock through open-market transactions at a weighted average price of $1.98 per share. These purchases, totaling $59,400, have increased his direct holdings to 366,904 shares, signal", "url": "https://www.stocktitan.net/sec-filings/PALI/form-4-palisade-bio-inc-insider-trading-activity-b7f6efe6f6ef.html", "source_name": "Stock Titan", "published_at": "2026-07-06T23:41:25", "published_display": "06 Jul 2026 23:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Palisade Bio Inc For: 6 July By Investing.com", "summary": "The article reports that Palisade Bio Inc. filed a Form 4 for July 6th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders to report changes in their ownership of company stock. The article provides minimal details b", "url": "https://ca.investing.com/news/stock-market-news/form-4-palisade-bio-inc-for-6-july-93CH-4722017", "source_name": "Investing.com Canada", "published_at": "2026-07-06T23:41:25", "published_display": "06 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palisade Bio, Inc. \u2013 NASDAQ:PALI", "summary": "This article focuses on the \"Price to book forward\" financial metric for Palisade Bio, Inc. (NASDAQ: PALI). It appears to be a financial data point provided by TradingView, without additional analysis or details. The content is primarily a data placeholder within a financial plat", "url": "https://www.tradingview.com/symbols/NASDAQ-PALI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T08:42:31", "published_display": "06 Jul 2026 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palisade Bio, Inc. \u2013 NASDAQ:PALI", "summary": "This article provides a brief snapshot of Palisade Bio, Inc. (NASDAQ: PALI) on TradingView, focusing on its financial overview. It mentions the company's stock information, market status, and available financial data. The content is primarily a data placeholder, indicating a lack", "url": "https://www.tradingview.com/symbols/NASDAQ-PALI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:10:24", "published_display": "04 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palisade-bio-gets-fda-ind-130329630.html", "source_name": "MT Newswires", "published_at": "2026-06-29T13:03:29+00:00", "published_display": "29 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palisade-bio-receives-fda-clearance-123000813.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T12:30:00+00:00", "published_display": "29 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-welcomes-biopharmaceutical-industry-124500803.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T12:45:00+00:00", "published_display": "11 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn\u2019s Disease at New York Academy of Sciences Symposium", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-present-potential-pali-124500883.html", "source_name": "GlobeNewswire", "published_at": "2026-06-09T12:45:00+00:00", "published_display": "09 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio to Participate in the Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palisade-bio-participate-jefferies-global-130000252.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T13:00:00+00:00", "published_display": "27 May 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQaHVrRV96dmxzcHNMZDQ2c2JVNThnTHZnNGFzX1UyU1U4NWtWcG0yeVh4UFJXN01oQ0h5dHN1YXJBUVVsR3c2YklWTHh5VUR6S2FUNy13QjhiVFk2ZlJtWDU1VTE0clZCMXBfdGdhRU5QSk5EektPdG1MQnctX0dqN2VEOWtfX3Ribnd2Q2pMbkNuRzhpeFIzTlRRbnU5Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palisade Bio Announces 1-for-15 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQQ0FIRDNzVHkyeW85dTRSbmw5bFYzWER4UjlDZUdaYnFON1diV1A0RE1Zd01JdW5uNHMtRE1kVElLbnFtZTZ4cFFjOTF6MGo3aGdyZVFyQ1BJVDNMY1p6VWk3aS0xdFVYYk42VXZDSEV1bHJqdzhBd1NnQXd3cGxsWmxHMXpjRUZ1N2tXTWJyZ0JxdDE5enMteEc0SHAtaEFqRFZsR3pBeEx4b3M3emlFVF9ILTZqV3U3OUJ3NlptQV82Ukdm?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-04-03T07:00:00+00:00", "published_display": "03 Apr 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 43, "sentiment_summary": {"positive": 11, "negative": 5, "neutral": 27, "score": 54, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 6.26, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.96, "latest_week": "2026-07-10", "one_week_move": -6.7, "four_week_move": 14.6, "twelve_week_move": -18.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.201398, "market_dynamics_buy_signal": false, "relative_strength": 1.980895, "fair_value_gap": -52.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.0848, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.7% over one week, +14.6% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 7}, {"label": "GlobeNewswire", "count": 6}, {"label": "Investing.com Nigeria", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 34}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "34", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.7% over one week, +14.6% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Palisade Bio director Robert Baltera Jr. purchases $88,698 in stock"}], "updated_at": "2026-07-18T03:33:42.905242+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}